Unlike past deals where Chinese firms kept only regional rights, new partnerships, like Hengri's with Bristol Myers, include options for co-commercialization globally. This signals a strategic shift from being regional R&D partners to becoming global commercial entities.

In a beverage market dominated by giants like Pepsi and Coke, Poppi's founders recognized that a strategic acquisition was the only path to global scale. They couldn't get into venues like stadiums due to existing contracts, so they intentionally built the company to be an attractive acquisition target.

The unpredictable nature of the Most Favored Nation (MFN) policy makes fixed launch plans obsolete. Companies must now create multiple, dynamic launch sequences tied to specific policy "signposts." This requires a shift towards continuous scenario planning and risk mitigation to remain prepared for various potential outcomes.

Even with a successful playbook from a company like Zoom, a marketing leader must adapt significantly when moving to a new context. Selling a physical product globally introduces complexities like homologation, customs, inventory, and channel sales that require eating 'humble pie' and learning the new business from the ground up.

While patents are important, a pharmaceutical giant's most durable competitive advantage is its ability to navigate complex global regulatory systems. This 'regulatory know-how' is a massive barrier to entry that startups cannot easily replicate, forcing them into acquisition by incumbents.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

RoboCath, a French startup, found that partnering with a local corporate or distributor is the most effective way to navigate the significant cultural and business differences in markets like the US and China, rather than attempting direct expansion.

Don't assume selling in Europe is the same as North America; it constitutes a new market entry. Companies often make a 'ton of assumptions' about marketing data, buying cycles, language, and regulations, underestimating the difficulty and risk of the move.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.